Abpro and Celltrion partner to develop antibody for cancer
Pharmaceutical Technology
SEPTEMBER 22, 2022
Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. According to preliminary data, the antibody has demonstrated enhanced efficacy and reduced toxicity versus other treatments for HER2+ cancer indication. .
Let's personalize your content